Michael CPA - Biostem Technologies Chief Officer
| BSEM Stock | USD 15.49 0.49 3.27% |
Insider
Michael CPA is Chief Officer of Biostem Technologies
| Phone | 954 380 8342 |
| Web | https://www.biostemtechnologies.com |
Biostem Technologies Management Efficiency
The company has return on total asset (ROA) of (0.6018) % which means that it has lost $0.6018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2102) %, meaning that it created substantial loss on money invested by shareholders. Biostem Technologies' management efficiency ratios could be used to measure how well Biostem Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew MBA | Monopar Therapeutics | 53 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Brian Sullivan | Celcuity LLC | 63 | |
| SPHR SHRMSCP | Ovid Therapeutics | N/A | |
| Hing Wong | HCW Biologics | 71 | |
| MBA MD | Ikena Oncology | 59 | |
| Lance Laing | Celcuity LLC | 63 | |
| Zoology Dphil | Ovid Therapeutics | 69 | |
| Joseph Hazelton | Dyadic International | 49 | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Sheri Smith | Celcuity LLC | N/A | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Jesse Shefferman | Protara Therapeutics | 53 | |
| Daniel Hicklin | Werewolf Therapeutics | 61 | |
| MBA MPH | Protara Therapeutics | 41 | |
| Pascal Prigent | Genfit | 57 | |
Management Performance
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 |
Biostem Technologies Leadership Team
Elected by the shareholders, the Biostem Technologies' board of directors comprises two types of representatives: Biostem Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostem. The board's role is to monitor Biostem Technologies' management team and ensure that shareholders' interests are well served. Biostem Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostem Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Irmgard MD, International Officer | ||
| Jason Matuszewski, Chairman and President and Secretary | ||
| Andrew VanVurst, COO Director | ||
| Larry Jones, Chief Officer | ||
| Michael CPA, Chief Officer | ||
| David Woynarowski, Chief Officer |
Biostem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Biostem Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 | |||
| Operating Margin | (18.22) % | |||
| Current Valuation | 37.89 M | |||
| Shares Outstanding | 9.24 M | |||
| Price To Earning | (0.49) X | |||
| Price To Sales | 151.81 X | |||
| Revenue | 2.52 M | |||
| Gross Profit | 163.78 K | |||
| EBITDA | (1.59 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.